GlassScriptPhysician profile
Ankur A Shah
NPI 1467956821
$14,405.44
in general payments reported to CMS, 2019-2025
30 companies · $4,205 in 2025
The $4,205 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $709 · 2023: $2,148 · 2024: $7,228 · 2025: $4,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $4,351 · Travel and Lodging: $2,080 · Consulting Fee: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $4,350.85 |
| Travel and Lodging | $2,080.46 |
| Consulting Fee | $1,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,055.27 | 2024-2025 | |
| Coloplast Corp | $3,154.52 | 2023-2025 | Titan |
| Janssen Scientific Affairs, LLC | $1,487.56 | 2025 | |
| Medtronic, INC. | $801.57 | 2021-2022 | |
| Procept Biorobotics Corporation | $665.49 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $157.31 | 2024 | Urolift |
| Pfizer INC. | $136.39 | 2023-2025 | |
| Janssen Biotech, INC. | $96.55 | 2025 | Erleada |
| Karl Storz Endoscopy-America | $96.18 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.99 | 2023-2024 | |
| Boston Scientific Corporation | $62.99 | 2022-2025 | General - Erectile Dysfunction, Spaceoar Vue System - 10ml |
| Dendreon Pharmaceuticals LLC | $59.45 | 2024-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $53.30 | 2024-2025 | |
| Endo USA, INC. | $53.19 | 2025 | Aveed, Xiaflex, Edex |
| Tolmar, INC. | $52.55 | 2024-2025 | Eligard |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.00 | 2024 | Keytruda |
| Endo Pharmaceuticals INC. | $48.32 | 2023-2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $42.12 | 2024-2025 | |
| Immunitybio, INC. | $38.33 | 2025 | |
| Blue Earth Diagnostics | $37.96 | 2024 | |
| Olympus America INC. | $23.81 | 2023 | Itind System |
| Progenics Pharmaceuticals, INC. | $23.49 | 2024 | |
| Telix Pharmaceuticals | $23.46 | 2024 | Illuccix |
| Laborie Medical Technologies Corp. | $21.08 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Astellas Pharma US INC | $20.48 | 2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $20.27 | 2024 | Orgovyx |
| Civco Medical Instruments | $19.61 | 2025 | |
| Antares Pharma, INC. | $19.28 | 2025 | Xyosted |
| Abbvie INC. | $18.92 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.